World Journal of
Pharmaceutical and Life Sciences

RECENT METHODS TO IMPROVE STABILITY PROFILE, PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES IN ANTICANCER DRUGS

Pravinkumar Darji*, Jayendrakumar Patel, Binit Patel, Arpan Chudasama, Praneeth Ivan Joel Fnu and Seshadri Nalla

ABSTRACT

Over the years, research on anticancer treatments has yielded impressive outcomes, although many of the drugs that have been approved still have significant systemic toxicity. This is primarily because these drugs lack selectivity for tumors and have pharmacokinetic limitations, such as low water solubility, which adversely impact their circulation time and bioavailability. The stability experiments conducted during the development of anticancer medications, either under benign settings or under exposure to high temperature, hydrolytic media, or light source, have revealed the susceptibility of these drugs to many factors. Therefore, the evaluation of degradation products is conducted in both pharmaceutical formulations and hospital waste in order to determine their production. So far, many formulations have been created to achieve drug targeting specific to certain tissues and to decrease harmful side effects, as well as to enhance drug stability. Prodrug development is a potential approach in targeted cancer therapy that aims to enhance the selectivity, effectiveness, and stability of active molecules. Recent research indicates that the inclusion of anticancer medications into vesicular systems, such as polymeric micelles or cyclodextrins, or the utilization of nanocarriers that contain chemotherapeutic agents conjugated to monoclonal antibodies, can enhance solubility, pharmacokinetics, cellular absorption, and stability. This paper provides a comprehensive overview of the most recent advancements in understanding the creation of potent and durable anticancer medications, which are designed as stable prodrugs or encapsulated in nanosystems.

[Full Text Article]   [Download Certificate]